One of the most common questions we are asked is about how personal genetic testing might impact medical costs, and how health insurers will deal with making decisions around covering certain sorts of genetic tests. In Business Week, John Lauerman tackles these subjects, looking specifically at genes related to Hypertrophic Cardiomyopathy (HCM), cancer risk, and its potential impact on families and children specifically.